Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease Read more
Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease Read more
Gilead Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19 Read more
Janssen Pharmaceutical exclusive interview released ahead of Pre-filled Syringes East Coast 2020 Read more
ImmunOs Therapeutics Selects ProBioGen for Development and Large-Scale Manufacturing Services Read more
Perrigo and Catalent Announce FDA Approval of Perrigo’s AB-Rated Generic Version of ProAir HFA Read more